An increase in hospital admissions in the US and UK has been associated with a new Covid-19 variation known as EG.5.1. While health organizations and specialists all over the world are keeping an eye on the spread of the virus, the World Health Organization (WHO) has added the Omicron subvariant, dubbed Eris, to its monitoring list.
A subvariant of the Covid-19 Omicron virus (B.1.1.529) is called EG.5.1. On social media, individuals and medical professionals have offered the name Eris, which is not the official one. The WHO has listed the virus among its “variants under monitoring (VUMs)” but has not yet designated it as a variant of concern or interest.
The EG.5.1 variant is “a little bit more slippery” and “competitive” than its counterparts because it can “navigate better the presence of antibodies” produced by vaccinations, claims Stuart Turville, virologist, researcher, and associate professor at the University of New South Wales in Sydney.
According to Turville, the ability of EG.5.1 to “engage and enter cells a little bit better” has only slightly improved upon that of other versions.
According to Professor K. Srinath Reddy at the Public Health Foundation of India, the subvariant EG.5 is a member of the Omicron subvariant family. According to a story in The Washington Post, the doctor claimed it is “less invasive and lethal to the body” and “this still remains the general observation”.
EG.5.1 “was first raised as a signal in monitoring on July 3, 2023 as part of horizon scanning due to increasing reports internationally, particularly in Asia,” according to the UK Health Security Agency (UKHSA).
Then, on July 31, EG.5.1 was formally designated as a variant “due to the increasing number of genomes in UK data, and continued growth internationally.”
According to the UKHSA, EG.5.1 was identified in 11.8% of the samples sequenced during the week beginning July 10 in the UK. With a weekly growth rate of 20.51 percent as of July 20, Eris has overtaken Arcturus as the second-most common variation in the UK at 14.55 percent. Meanwhile, 39.35% of all cases in the UK involve Arcturus.
Eris is now the most common Covid-19 version in the US. In the two weeks that ended on August 5, it had a prevalence of 17.3%, according to the Centers for Disease Control and Prevention (CDC).
Eris has also been shown to exist in Pune, a city in western India. The Times of India quoted Dr. Rajesh Karyakarte, the state of Maharashtra’s genome sequencing coordinator, as saying that “EG.5.1 was detected in Maharashtra in May.”
Omicron and EG.5.1 are thought to have comparable symptoms.
These include, among others, a sore throat, coughing, changes in smell, headache, sneezing, and exhaustion.